2021 American Transplant Congress
The Learning Curve Associated with De Novo Tacrolimus XR Use in a Racially Diverse Kidney Transplant Population
Medical University of South Carolina, Charleston, SC
*Purpose: Tacrolimus XR (LCP-Tac) was approved for de novo dosing in kidney transplant recipients in 2018. In 2020, our center was challenged with a nationwide…2021 American Transplant Congress
Ectopic Hepatocyte Transplantation Into the Lymph Nodes in a Fully Mismatched Allogeneic Dog Model Using Tacrolimus and Prednisone
*Purpose: Develop organogenesis through ectopic hepatocyte transplantation (HT) into the upper abdominal lymph nodes (LN).*Methods: Three groups of Mongrel dogs weighting between 25-35 kg (control…2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…2021 American Transplant Congress
Tacrolimus Dose Requirements in Lung Transplant Recipients on Systemic Azole Antifungals: The Influence of Race and Transplant Indication
*Purpose: CYP3A5 polymorphisms, drug interactions, and alterations in gastric absorption impact tacrolimus metabolism. This is important for those at higher risk of expressing these factors,…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…2020 American Transplant Congress
Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…2020 American Transplant Congress
The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics
*Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…2020 American Transplant Congress
Envarsus XR Use Can Benefit Serum Creatinine Levels in Vascularized Composite Allotransplantation Patients
*Purpose: Vascularized composite allotransplantation (VCA) is a life-enhancing (as opposed to life-saving) procedure. Therefore, minimizing adverse outcomes associated with chronic immunosuppression is vital to determining…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »